We are live on ! Find out more
PPH icon

VanEck Pharmaceutical ETF
PPH

91 hedge funds and large institutions have $346M invested in VanEck Pharmaceutical ETF in 2022 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 35 increasing their positions, 8 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

392% more capital invested

Capital invested by funds: $70.5M → $346M (+$276M)

338% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 8

317% more call options, than puts

Call options by funds: $4.83M | Put options by funds: $1.16M

170% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 10

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

45.3% more ownership

Funds ownership: 19.22% → 64.52% (+45%)

21% more funds holding

Funds holding: 75 → 91 (+16)

Holders
91
Holders Change
+16
Holders Change %
+21.33%
% of All Funds
1.53%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
27
Increased
35
Reduced
8
Closed
10
Calls
$4.83M
Puts
$1.16M
Net Calls
+$3.67M
Net Calls Change
+$4.25M

Top Buyers

Rank Fund Capital Flow
1
PF
Phoenix Financial
Israel
+$164M
2
UBS Group
UBS Group
Switzerland
+$37.6M
3
Goldman Sachs
Goldman Sachs
New York
+$16.6M
4
Morgan Stanley
Morgan Stanley
New York
+$11.5M
5
NC
Noked Capital
Israel
+$10.9M

Top Sellers

Rank Fund Capital Flow
1
CCP
Clough Capital Partners
Massachusetts
-$2.77M
2
LJAC
L.J. Altfest & Co
New York
-$1.42M
3
Citadel Advisors
Citadel Advisors
Florida
-$946K
4
GA
GFS Advisors
Texas
-$518K
5
CS
Credit Suisse
Switzerland
-$504K
Name Holding Trade Value Shares
Change 		Change in
Stake
HPC
76
HM Payson & Co
Maine
$19K – – –
RCM
77
Raleigh Capital Management
North Carolina
$19K +$78 +1 +0.4%
SWM
78
SeaCrest Wealth Management
New York
$19K +$19.5K +250 New
William Blair & Company
79
William Blair & Company
Illinois
$15K – – –
LFA
80
Level Financial Advisors
New York
$14K +$13.9K +178 New
HCM
81
Highlander Capital Management
New Jersey
$11K – – –
NC
82
NewSquare Capital
Pennsylvania
$7K – – –
BBPWM
83
Blue Bell Private Wealth Management
Pennsylvania
$6K – – –
SPIA
84
Steward Partners Investment Advisory
New York
$6K – – –
JWA
85
JFS Wealth Advisors
Pennsylvania
$5K +$5K +64 New
AIM
86
Anchor Investment Management
South Carolina
$4.46K – – –
VanEck Associates
87
VanEck Associates
New York
$4K – – –
MIM
88
Macroview Investment Management
Maryland
$3K +$3.04K +39 New
SWA
89
SOA Wealth Advisors
New York
$2K – – –
Bank of Montreal
90
Bank of Montreal
Ontario, Canada
$150 -$7.81K -100 -5%
CCP
91
Clough Capital Partners
Massachusetts
– -$2.77M -34,700 Closed
Citadel Advisors
92
Citadel Advisors
Florida
– -$946K -12,120 Closed
GA
93
GFS Advisors
Texas
– -$518K -6,500 Closed
CS
94
Credit Suisse
Switzerland
– -$504K -6,323 Closed
DAS
95
Dynamic Advisor Solutions
Arizona
– -$413K -5,173 Closed
TCM
96
Tradewinds Capital Management
Washington
– -$80K -1,000 Closed
S
97
SignatureFD
Georgia
– -$28K -355 Closed
MCC
98
Money Concepts Capital
Florida
– -$21K -269 Closed
SSG
99
Summit Securities Group
New York
– -$16K -200 Closed
CG
100
Cutler Group
California
– -$7.81K -100 Closed
1 2 3
4

PPH Hedge Fund Activity: Q2 2022 in Review

91 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q2 2022, worth a combined $346M — up 392% from $70.5M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new PPH positions and 10 closed out — a net gain of 17 holders — while 35 added to existing stakes and 8 trimmed.

The largest buyer was Phoenix Financial, adding an estimated $164M. The largest seller was Clough Capital Partners, exiting entirely with an estimated $2.77M sold.

  • 91 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q2 2022, up from 75 in Q1 2022.
  • Funds reported $346M of VanEck Pharmaceutical ETF stock for Q2 2022, up 392% quarter-over-quarter.
  • 27 funds opened new VanEck Pharmaceutical ETF positions in Q2 2022 and 10 closed out, a net change of +17 holders.
  • The largest VanEck Pharmaceutical ETF buyer in Q2 2022 was Phoenix Financial, an estimated $164M added.
  • The largest VanEck Pharmaceutical ETF seller in Q2 2022 was Clough Capital Partners, an estimated $2.77M sold.

Based on aggregated 13F filings for Q2 2022.